Global /Canada /Healthcare /Drug Manufacturers - General /RVX

Resverlogix Corp.

RVX

• TSX: RVX • Delayed

0.0950CAD -5%

0.0681 USD

As of 6 June 2026, Resverlogix Corp. has a market cap of $21.57M USD, ranking #36600 globally and #1286 in Canada. It ranks #3285 in the Healthcare sector, and #1100 in the Drug Manufacturers - General industry.

Global Rank

36600

Country Rank

1286

Sector Rank

3285

Industry Rank

1100

Key Stats

Market Cap

$21.57MUSD

30.08M CAD

Enterprise Value

$105.89MUSD

147.71M CAD

EBITDA (TTM)

-$4.4MUSD

-6.14M CAD

Net Income (TTM)

-$7.63MUSD

-10.65M CAD

PB Ratio

-0.2

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Donald McCaffrey open_in_new

Employees

Website

resverlogix.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-5%	-5%	-14%	-5%	-17%	-5%	138%	-37%	-90%

News

Markets

Exchange	Ticker	Price	Quotes
Toronto Stock Exchange (TSX) MIC: XTSE PRIMARY	RVX Resverlogix Corp ISIN: CA76128M1086 Shares Out.: Shares Outstanding: 343.842M¹ Shares Float: 242.63M² TV: TradingView: TSX: RVX SA: Stock Analysis: TSX: RVX YF: Yahoo Finance: RVX.TO GF: Google Finance: TSE: RVX BA: Barron's: RVX MS: Morningstar: XTSE: RVX	0.0950 CAD	TV: TradingView: TSX: RVX SA: Stock Analysis: TSX: RVX YF: Yahoo Finance: RVX.TO GF: Google Finance: TSE: RVX BA: Barron's: RVX MS: Morningstar: XTSE: RVX
London Stock Exchange (LSE / LON) MIC: XLON	0VF9 Resverlogix Corp ISIN: CA76128M1086 Shares Out.: Shares Outstanding: 315.917M¹ Shares Float: 213.775M² TV: TradingView: LSE: 0VF9 SA: Stock Analysis: LON: 0VF9 YF: Yahoo Finance: 0VF9.L GF: Google Finance: LON: 0VF9 BA: Barron's: 0VF9 MS: Morningstar: XLON: 0VF9	0.1150 CAD	TV: TradingView: LSE: 0VF9 SA: Stock Analysis: LON: 0VF9 YF: Yahoo Finance: 0VF9.L GF: Google Finance: LON: 0VF9 BA: Barron's: 0VF9 MS: Morningstar: XLON: 0VF9
Cboe Canada (NEO) MIC: NEOE	RVX Resverlogix Corp ISIN: CA76128M1086 TV: TradingView: NEO: RVX SA: Stock Analysis: NEO: RVX YF: Yahoo Finance: RVX.NE GF: Google Finance: NEO: RVX BA: Barron's: RVX MS: Morningstar: NEOE: RVX	0.0950 CAD	TV: TradingView: NEO: RVX SA: Stock Analysis: NEO: RVX YF: Yahoo Finance: RVX.NE GF: Google Finance: NEO: RVX BA: Barron's: RVX MS: Morningstar: NEOE: RVX
OTC Markets (OTCMKTS / OTC) MIC: OTCM	RVXCF Resverlogix Corp ISIN: CA76128M1086 Shares Out.: Shares Outstanding: 284.638M¹ Shares Float: 190.928M² TV: TradingView: OTC: RVXCF SA: Stock Analysis: OTC: RVXCF YF: Yahoo Finance: RVXCF GF: Google Finance: OTCMKTS: RVXCF BA: Barron's: RVXCF MS: Morningstar: PINX: RVXCF	0.0700 USD	TV: TradingView: OTC: RVXCF SA: Stock Analysis: OTC: RVXCF YF: Yahoo Finance: RVXCF GF: Google Finance: OTCMKTS: RVXCF BA: Barron's: RVXCF MS: Morningstar: PINX: RVXCF

Show all 4 markets

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Resverlogix Corp.

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

Similar Companies

Industry: Drug Manufacturers - General (Canada)

Name	Market Cap (USD) diff.	PE	Country
Xenon Pharmaceuticals Inc. NASDAQ: XENE	$5.39B 25K%	-	Canada
Knight Therapeutics Inc. TSX: GUD	$519.8M 725.1M CAD 2K%	-	Canada
Milestone Pharmaceuticals Inc. NASDAQ: MIST	$223.22M 935%	-	Canada
Satellos Bioscience Inc. TSX: MSCL	$155.46M 216.85M CAD 621%	-	Canada
BioSyent Inc. TSXV: RX	$118.9M 165.86M CAD 451%	18.5	Canada
Helix BioPharma Corp. TSX: HBP	$110.6M 154.28M CAD 413%	-	Canada

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 4M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 3M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 2M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 2M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 1M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 1M%	20.5	Switzerland

chevron_leftBack